- Global Pharma News & Resources

APOL1 Mediated Kidney Disease Market Research with Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis and Challenges, Forecast to 2022-2030

The current treatment options are limited and they are effective only against the symptoms of APOL1 medicated kidney diseases such as inflammations, high fluid volume, and hypertension. Because of this, there is an urgency of novel and targeted therapeutics which can target to reduce APOL1 protein level in the body. Excess APOL1 causes nephropathic conditions and ultimately kidney failure in people having APOL1 mediated disorder.

According to a latest report published by Future Market Insights (FMI), the global APOL1 mediated kidney disease market was valued at US$ 3.0 Bn in 2020 and is anticipated to witness a steady CAGR of over 4% during the forecast period (2020-2030).

Ask for the Comprehensive Report Sample:

Currently, the leading clinical stage biopharmaceutical developers are focusing on development of next generation targeted therapeutics against APOL1 medicated kidney diseases, specifically chronic kidney diseases. The promising yet unmet opportunities for APOL1 medicated kidney diseases are attracting established and new biopharmaceuticals to dive in the targeted therapeutic based approach. This trend is expected to offer competitive-edge and exclusive monopoly in the global market in the future.

For instance, in 2018, AstraZeneca closed a $330 million licensing agreement for two pipeline antisense therapies of Ionis Pharmaceuticals, Inc. a U. S. based clinical stage Innovator Company engaged in the advanced research of rare diseases. One of licensed therapeutic is investigational novel antisense drug (AZD2373) to treat original cause of the APOL1 mediated chronic kidney diseases. AZD2373 is currently under clinical phase I and is looking a promising candidate for the future APOL1 mediated kidney diseases landscape.

Key Takeaways from APOL1 Mediated kidney Diseases Market Study

  • Chronic kidney diseases account for more than 95% of all the APOL1 mediated diseases. Increasing prevalence of hypertension associated kidney diseases will increase treatment needs over the forecast period
  • North America accounts for over 3/4th of the global market. High prevalence of the disease among people with African American ancestry makes North America the leader in this market
  • Pipeline drugs under development are targeted to be launched in the U.S., catapulting it as a highly lucrative pocket
  • Key players are focusing on extensive research and development for targeted therapy towards APOL1
  • The COVID-19 outbreak did not have any impact on the APOl1 mediated treatment market. All patients with indications like end stage kidney disorders were attended amidst COVID-19 due to the severity of kidney disease

“Increasing research and development for discovery of underlying cause of APOL1 mediated kidney disease and its targeted therapy will propel the market growth in the future,” says FMI analyst

Who is winning?

Collaboration is the key strategy amongst market players. Companies research on APOL1 therapies are strengthening their chances of successful clinical trials by collaborating with prominent pharma players. Increasing investments in drug discovery is expected to favor the growth the global market over the forecast period

  • For instance, Ionis Pharma has collaborated with AstraZeneca for developing its molecule which is currently under clinical trial phase 1.

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015-2030. The global APOL1 mediated kidney disease market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on APOL1 mediated kidney disease (Symptomatic Treatment) market on basis of indication (Chronic Kidney Disease and End Stage Kidney Disease) across North America, Europe and Middle East and Africa and APOL1 mediated kidney disease (Pipeline Therapeutics) market on basis of indication (Chronic Kidney Disease and End Stage Kidney Disease) across North America (U.S.)

Ask for the complete TOC of this Report:

About the Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
​United Arab Emirates
For Sales Enquiries:
For Media Enquiries:

Editor Details

Last Updated: 17-Mar-2022